A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorCentessa Pharmaceuticals (UK) Limited
About this trial
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Eligibility criteria
Qualifiers
Healthy males or females as determined by assessments at the Screening Visit.
For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening
Disqualifiers
Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
History of seizure disorder, any other condition that increases the risk of seizure
Has a clinically significant sleep disorder, including insomnia or sleep apnea
Trial design
Treatments tested in this trial
- ORX489 Tablets
- Placebo Tablets
Treatment groups
212 Participants
are divided into 4 treatment groupsLocations
1Celerion68502, LincolnNebraska, United States
Sponsors and collaborators
Centessa Pharmaceuticals (UK) Limited
Lead sponsor
Source ClinicalTrials.gov